Mountz v. Global Vision Products, Inc.

3 Misc. 3d 171, 770 N.Y.S.2d 603, 2003 N.Y. Misc. LEXIS 1619
CourtNew York Supreme Court
DecidedDecember 17, 2003
StatusPublished
Cited by18 cases

This text of 3 Misc. 3d 171 (Mountz v. Global Vision Products, Inc.) is published on Counsel Stack Legal Research, covering New York Supreme Court primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Mountz v. Global Vision Products, Inc., 3 Misc. 3d 171, 770 N.Y.S.2d 603, 2003 N.Y. Misc. LEXIS 1619 (N.Y. Super. Ct. 2003).

Opinion

OPINION OF THE COURT

Diane A. Lebedeff, J.

The plaintiffs are purchasers of Avacor, a hair loss treatment extensively advertised on television, in print and on the Internet. Their pleading, in essence, portrays the marketing techniques for Avacor as the modern day equivalent of the sales pitch of a snake oil salesman, against which plaintiffs primarily seek to invoke Maine consumer protection statutes urged to be applicable because the seller receives orders for Avacor in, and ships its product from, the State of Maine. Although the [173]*173complaint contains class action allegations, no motion yet has been made to certify a class.

Defendant Global Vision Products, Inc. (GVP), which markets Avacor, is a New York corporation with offices in New York. Defendant Anthony Imbriolo is GVP’s president and founder. These two defendants move for dismissal of the complaint, and its class action allegations, upon the assertion that the complaint fails to state a cause of action (CPLR 3211 [a] [7]), request summary judgment because they offer a money back guarantee (CPLR 3212), and seek an injunction restraining plaintiffs from litigating the same issues in other jurisdictions.

Defendant Gordon, who is further described below, also requests dismissal of the claims against him, albeit not by the submission of a formal cross motion for relief. Given that he made an earlier motion to dismiss the original pleading, which was denied with leave to renew in relation to the amended pleading, the court deems him also a moving party. It is noted that the court previously dismissed the claims raised against Derrike Cope, a race car driver endorsing Avacor as a part of the product’s sales campaign, on jurisdictional grounds and the caption is amended to reflect such dismissal.

Background

Avacor is a trio of items — together represented to be “all-natural,” “herbal,” “clinically proven,” and “revolutionary”— which includes a shampoo, “herbal based topical formulation,” and nutritional supplement. It is beyond dispute that Avacor’s topical solution actually contains minoxidil, the main active ingredient in Rogaine.

Plaintiffs assert the defendants’ claim of “no known side effects” of Avacor is refuted by documented minoxidil side effects, which include cardiac changes, visual disturbances, vomiting, facial swelling and exacerbation of hair loss, among others. Plaintiffs urge Avacor is a drug within the meaning of 21 USC § 321 (g) (1) (B) and (p) (1), requiring United States Food and Drug Administration (FDA) approval prior to distribution in interstate commerce under 21 USC § 355 (a). Further, given the nutritional and dietary supplement claims made on behalf of Avacor’s nutritional pills, plaintiffs plead such pills fail to meet the substantive and disclaimer labeling standards of 21 USC § 343 (r) (3), a subdivision of the Dietary Supplement Health Education Act.

The plaintiffs assert that the disclosure on the label that Ava-cor contains “2, 4-diamino-6-piperidino-pyramidine-3-oxide,” [174]*174the chemical representation of minoxidil, is not a meaningful substitute for proper disclosure. On or about February 10, 2003, after plaintiffs filed this suit and after the composition of Ava-cor and the lack of the requisite product warnings came to the attention of the FDA, GVP announced that it would change the labeling to provide proper disclosure, give relevant warnings, and discontinue the claim the product was “all natural” and had a success rate of more than 90%. The court has not been advised whether such changes have been implemented.

The amended complaint references these facts and further alleges that the promotion of Avacor includes fallacious references that Avacor was “extensively tested” and used at the Hair & Skin Treatment Center and the New York Hair Clinic. Both are pleaded to have offices physically contiguous with GVP’s office, to have never offered services utilizing Avacor, and to have never provided treatment to clients. The complaint contends the reprinted “medical study” shipped with Avacor also falsely reports (1) research conducted at these inoperative facilities and (2) a “90% success rate” without support from a sound clinical study.

The complaint charges GVP’s president, defendant Imbriolo, is a coauthor of this study and is not identified by his corporate relationship and interest in the product. Further, it is alleged that defendant Gordon — portrayed in advertising as a doctor, identified as “Medical Director” of one of the clinics referenced above, and an endorser of the product — is actually a former physician who was stripped of his medical license following a conviction for Medicaid fraud.

In relation to the money back guarantee, GVP offers a full refund of the purchase price, less the shipping charge, for a guarantee period running from the date of the delivery for the same number of months as the monthly supply of Avacor purchased. If the product is not fully used, the remaining product must be returned. Taking the figures supplied by an officer of GVP and adjusting them to an annual basis, annual orders in the past have been roughly between $10 and $13 million, of which approximately $2.3 million is refunded a year, representing 17% to 20% of the purchases. It is asserted that approximately 35% of purchasers order the product again.

As to damages, the complaint alleges that the shampoo and nutritional supplement add no value to the topical solution, resulting in the consumer paying a purchase price for Avacor that is 300% greater than the purchase price for other minoxidil [175]*175solutions. The plaintiffs request monetary recoupment of the purchase price of the product, an injunction against unlawful practices, and related relief.

Maine Consumer Protection Statutory Claims

Defendants seek dismissal of the causes of action alleging violations of Maine’s Deceptive Trade Practices Act (Maine DTPA) (Me Rev Stat Ann, tit 10, § 1211 et seq.) and Maine’s Unfair Trade Practice Act (Maine UTPA) (Me Rev Stat Ann, tit 5, § 205-A et seq.).

As to the second cause of action which seeks damages only and pleads a violation of the Maine’s DTPA, defendants correctly urge that the damages claim must fall because only injunctive relief is available under that statute (Me Stat Ann, tit 10, § 1213; see, generally describing statute, Sebago Lake Camps, Inc. v Simpson, 434 A2d 519 [Sup Jud Ct Me 1981]). Accordingly, this monetary claim is severed and dismissed.

In relation to the Maine UTPA claim, the statute applies to “unfair or deceptive acts or practices in the conduct of any trade or commerce” (Me Rev Stat Ann, tit 5, § 207). It is recognized that “[n]either term as used in Maine’s UTPA can be precisely defined, and their applicability should be determined on a case by case basis” (Guiggey v Bombardier, 615 A2d 1169, 1172 [Sup Jud Ct Me 1992]).

As to the claim for Maine UTPA monetary relief, defendants contend dismissal must occur because plaintiffs did not properly comply with Maine’s requirement that plaintiffs make a written demand for relief to a potential defendant at least 30 days prior to the filing of such an action for damages, which allows a defendant a period of time to offer to pay such damages (Me Rev Stat Ann, tit 5, § 213 [1-A]). This objection does not support dismissal under Maine law (Oceanside at Pine Point Condominium Owners Assn. v Peachtree Doors, Inc.,

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Aminov v. Draftkings Inc.
E.D. New York, 2025
CALLERY v. HOP ENERGY, LLC
E.D. Pennsylvania, 2023
Wright v. Publishers Clearing House, Inc.
372 F. Supp. 3d 61 (E.D. New York, 2019)
Reynolds v. Lifewatch, Inc.
136 F. Supp. 3d 503 (S.D. New York, 2015)
Cruz v. FXDirectDealer, LLC
720 F.3d 115 (Second Circuit, 2013)
Zaycer v. Sturm Foods, Inc.
896 F. Supp. 2d 399 (D. Maryland, 2012)
Preira v. Bancorp Bank
885 F. Supp. 2d 672 (S.D. New York, 2012)
Bel Canto Design, Ltd. v. MSS HiFi, Inc.
837 F. Supp. 2d 208 (S.D. New York, 2011)
Gavin v. AT&T CORP.
543 F. Supp. 2d 885 (N.D. Illinois, 2008)
Thomas v. Metropolitan Life Insurance
540 F. Supp. 2d 1212 (W.D. Oklahoma, 2008)
Leider v. Ralfe
387 F. Supp. 2d 283 (S.D. New York, 2005)
Mountz v. Global Vision Prods., Inc.
2003 NY Slip Op 23905 (New York Supreme Court, 2003)

Cite This Page — Counsel Stack

Bluebook (online)
3 Misc. 3d 171, 770 N.Y.S.2d 603, 2003 N.Y. Misc. LEXIS 1619, Counsel Stack Legal Research, https://law.counselstack.com/opinion/mountz-v-global-vision-products-inc-nysupct-2003.